Novo Nordisk faced another tough earnings season, with the stock falling 30% after it revised its growth guidance due to increased competition from Eli Lilly and the (now-illegal) compounders. This has brought the stock down to a tantalizing 12x earnings. Is this a great time to pick up shares, or are investors risking catching a falling knife? Novo is attempting to fend off the competition by launching its own direct-to-consumer Wegovy service in the United States, which will sell its drugs for $499 a month—less than half the previous cash price. Combined with a new management team, Novo has a lot of irons in the fire. Perhaps these efforts will bolster its long-term outlook.

Later, Emmet discusses the impact of AI investment on the broader economy. Emerging in the midst of the 2023 market downturn, the AI race has spurred an extreme infrastructure spending boom from tech companies, especially the Magnificent Seven. They’ve pumped $151 billion into the economy so far. Is it a bubble, or the new normal in tech?

Mike and Emmet also touch on Elon Musk's $30 billion pay day. Is this infamous CEO still worth the premium?

Five lucky listeners can claim a complimentary ticket to Investicon when they sign up for Horizon. To hear more about the offer and claim your ticket, email us.

pod@mywallst.com

Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: pod@mywallst.com

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

🐦 Twitter: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt

00:00 Stock Market Sentiment and Initial Discussion

01:52 Elon Musk’s $30 Billion Pay Day

09:01 Deep Dive into Novo Nordisk

21:35 Nova's Billion-Dollar Sales and Competitive Landscape

28:18 The Future of AI and Its Economic Impact

#273: Is Novo Nordisk a Buy? An Undervalued Stock or Falling Knife?

Stock Club